Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the appropriate dose and safety of a preventative dose of fondaparinux, an anticoagulant medication (blood thinner) in patients with kidney disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

NCT01121770

Renal Insufficiency

COMPLETED PHASE1

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

NCT00256100

Renal Failure

TERMINATED NA

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05027074

End-Stage Renal Disease End-Stage Kidney Disease Kidney Failure, Chronic

COMPLETED PHASE2

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

NCT03289520

Kidney Failure Hemodialysis Fistula Thrombosis

COMPLETED PHASE3

Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

NCT00035178

Kidney Failure, Chronic Renal Disease, End-Stage

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will evaluate the PK of fondaparinux in patients who have renal insufficiency. Fondaparinux is cleared from the body mainly by the kidneys. Therefore in patients with kidney diseases, full doses of fondaparinux could cause bleeding problems. The correct dose of fondaparinux that should be used in patients with kidney disease is not known. The purpose of this research is to determine the PK and safety of a preventative dose (2.5mg subcutaneously every other day) of fondaparinux for patients with kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no arms/one group

Group Type EXPERIMENTAL

fondaparinux

Intervention Type DRUG

injections of 2.5mg every other day for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fondaparinux

injections of 2.5mg every other day for 4 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Arixtra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients in the Medicine and Nephrology clinics who are 18 years or older,
* Outpatients in the Medicine and Nephrology clinics who have an estimated creatinine clearances between 20-30ml/min,
* Outpatients in the Medicine and Nephrology clinics who are able to give consent will be included.

Exclusion Criteria

* anticoagulation therapy for thrombosis or other indication
* pregnant or breast-feeding
* hypersensitivity to fondaparinux
* subjects also will be excluded if there is concern for an increased risk of bleeding which includes the following:

* known bleeding disorder (see Section 8. Hemostatic Assessment)
* blood transfusion in the past 3 months
* acute ulcer disease with past 3 months
* platelet count \< 120,000 mm3
* prolonged baseline prothrombin time (PT) or activated partial thromboplastin time (aPTT) above upper limit of normal laboratory range
* major trauma or surgery within two weeks prior to enrollment
* history of intracranial hemorrhage

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No